COVID-19

A study indicates that possible disruptions in skin cancer screenings and general dermatologic care at the time of the pandemic could have resulted in fewer diagnoses of melanoma generally.

Bivalent COVID-19 vaccines by both Moderna and Pfizer-BioNTech are no longer authorized for use in the United States.

A new study found that 1 in 8 older adults with cancer and no history of depression developed the condition for the first time during the COVID-19 pandemic.

Previous clinical data has shown that the vaccine also generates a strong response to the EG.5 and FL.1.5.1 variants.

Study authors conclude that all children should be up to date with recommended COVID-19 vaccines and initiate the vaccination process immediately when products become available.

The CDC and WHO are currently tracking several variants that are driving the majority of new cases around the world.

A study published in the Lancet found that patients who had previously tested positive for COVID-19 had lower cognitive accuracy compared to negative controls.

A 510(k) clearance, or a Premarket Notification, requires device manufacturers to notify the FDA at least 90 days ahead of registration with their intent to market a medical device.

Although wastewater data and COVID case/hospitalization rates no longer accurately reflect each other, researchers suggest wastewater surveillance may be the best metric for monitoring the amount of circulating virus.

Moderna’s mRNA-1273 vaccine was associated with a lower risk of diagnosed COVID-19 when compared to Pfizer’s BNT162b2.

A study from Bavaria, Germany, found the frequency was higher among boys and children younger than the median age of 6.5 years during the pandemic.

Children who tested positive were more likely to report long COVID symptoms at 90 days than children who tested negative.

The report references adult vaccines, in terms of volume of use, for influenza, diphtheria and tetanus (Td), diphtheria, tetanus and pertussis (TDaP), hepatitis B, herpes zoster and pneumococcal.

Investigators found significant associations between GI-PACS and multi-system concomitant symptoms.

Post-acute sequelae of SARS-CoV-2 infection (PASC) is a complex condition involving multiple organ systems.

The COVID-19 public health emergency is over. What happens now?

Fewer hospitalized patients with COVID-19 pneumonia died when treated with standard care plus either infliximab or abatacept.

Heterologous vaccination—or mixing different vaccines—was safe and effective with Novavax and provided enhanced protection against the Omicron variant, a new study found.

Pending authorization of the XBB.1.5 vaccine, the company said that doses would be available in time for fall vaccination.

In a large observational study, significant information was obtained about mRNA vaccine protection against acute infection and disease severity.

The VRBPAC committee voted 21-0 in favor of this recommendation.

The newly approved at-home test was effective in trials, correctly identifying 98.7% of negative and 92.9% of positive samples for individuals with symptoms of upper respiratory infection.

Patients were more likely to require ICU admission.

New research suggests that chronotropic incompetence contributes to exercise limitations in Long COVID.

More than 11.6 million treatment courses of the medication have been prescribed in the U.S. to date.

Finalizing a definition for postacute sequelae of SARS-CoV-2 infection will lead to high-quality care and treatment for patients suffering from the condition.

Quality of life (QOL) for people living with autoimmune diseases benefits from an integrated approach that considers individual immune system sensitivities and patients’ life circumstances, a new study shows.

New data from Digestive Disease Week furthers evidence that biologics can be effective

Data presented at Digestive Disease Week show that patients with IBD had less intense post-vaccination symptoms after a fourth dose.

According to commentaries published in the Annals of Internal Medicine, doctors remain split on the question.